Yttriumcitrat (90y) Curium Germany

Yttrium (90Y) Citrate is a radiopharmaceutical used for intraarticular therapy. This sterile, non-pyrogenic solution is indicated for synovectomy in select patients. Always handled by healthcare professionals due to its radioactive properties.

Yttrium (90Y) Citrate is primarily used for radiation synovectomy in patients with chronic synovitis, particularly in joints unresponsive to conventional therapies. It delivers localized radiation to reduce inflammation and pain in affected joints. This treatment is typically reserved for cases where systemic medications have proven ineffective.

Following intraarticular administration, Yttrium (90Y) Citrate emits beta radiation that targets inflamed synovial tissue. Patients may experience gradual reduction in joint swelling and discomfort over several weeks. The effects are localized to the injection site, minimizing systemic impact.

Yttrium (90Y) Citrate must be administered by trained medical professionals in a controlled setting. Protective measures, including shielding and proper disposal protocols, are essential due to its radioactive nature. Pregnant individuals and those breastfeeding should avoid exposure to this medication.

As a radiopharmaceutical, Yttrium (90Y) Citrate does not interact with other medications in the traditional sense. However, concurrent use of other radioactive treatments or external beam radiation should be avoided to prevent overlapping exposure. Always inform healthcare providers about all medications and treatments being used.